In this study, we found the impact of cancer stemness on immunotherapy responses to pancreatic cancer and identified CEACAM5 as a candidate stemness-related inhibitory immune checkpoint in pancreatic cancer. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.